Abstract

Nutritional Therapy in Very Early-Onset Inflammatory Bowel Disease: A Case Report

Miller TL1, Lee D2, Giefer M2, Wahbeh G2, Suskind DL2. Dig Dis Sci. 2017 May 27. doi: 10.1007/s10620-017-4616-9. [Epub ahead of print]
 
     
Author information

1 Department of Pediatrics, Seattle Children's Hospital and University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA. talya.miller@seattlechildrens.org. 2 Department of Pediatrics, Seattle Children's Hospital and University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA.

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract caused by a dysregulated immune response to the fecal microbiota. Very early-onset inflammatory bowel disease (VEO-IBD) refers to a subgroup of pediatric patients with IBD diagnosed before 6 years of age. This subgroup is often characterized by increased severity, aggressive progression, strong family history of IBD, and often poor response to conventional treatments. Nutritional therapies have been utilized to treat IBD, but their role in VEO-IBD is unclear. Disease behavior in VEO-IBD is often different from disease in adolescents and adults, as it is often restricted to the colon and refractory to standard medical therapies. Up to 25% of VEO-IBD patients have an identified underlying immunodeficiency, which may impact response to therapy. While specific mutations in interleukin 10 (IL-10), the IL-10 receptor (IL-10R), and mutations in NCF2, XIAP, LRBA, and TTC7 have been identified in VEO-IBD, polymorphisms in these genes are also associated with increased risk of developing IBD in adolescence or adulthood. We describe two cases in which infants presenting with VEO-IBD achieved clinical remission using exclusive enteral nutrition, a formula-based diet which has been shown to induce remission in older children with active Crohn's disease.

© Copyright 2013-2017 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.